Gurnee, IL, United States of America

Tom C Harris

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Abbvie Deutschland Gmbh and Co Kg, Abbvie Inc.. Active years: 2013.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Tom C Harris

Introduction

Tom C Harris is a notable inventor based in Gurnee, IL (US). He has made significant contributions to the field of medical treatments, particularly in the area of psoriasis. His innovative approach has led to the development of methods that utilize antibodies to target specific subunits of interleukins.

Latest Patents

Harris holds a patent for "Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23." This invention provides methods of treating psoriasis in a subject by administering an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. This patent highlights his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Throughout his career, Tom C Harris has worked with prominent companies in the pharmaceutical industry, including AbbVie Inc. and AbbVie Deutschland GmbH & Co. KG. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research.

Collaborations

Harris has collaborated with notable professionals in his field, including Yanjun Bao and Elliot Keith Chartash. These partnerships have further enhanced his work and expanded the impact of his inventions.

Conclusion

Tom C Harris is a distinguished inventor whose work in treating psoriasis has the potential to change lives. His innovative methods and collaborations reflect his dedication to advancing medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…